August 11, 2005 Genzyme and Biogen Idec settled their royalty lawsuit against Columbia University over a technique that dates from the 1970s, CV Therapeutics said regadenoson met its primary endpoint in the first of two Phase III trials, Advanced Magnetics accepted an FDA request for an additional test in a Phase III trial, Barr Labs won FDA approval for a generic form of Roche’s Klonopin wafer, Halozyme Therapeutics won FDA approval to begin trials of a bladder cancer drug, and Theragenics cut 8.5% of its employees and sold off facilities to concentrate on its two money-making products. Overall, biotech enjoyed an across-the-board rise in share prices on Thursday, with the Centient Biotech 200 some 55 points higher at 3746.12, a rise of 1.48%, the best gain in August.
